Norovirus VLP vaccine: Phase I/II started

LigoCyte began a double-blind, placebo-controlled, U.S. Phase I/II trial to evaluate 2 doses of 100 µg of its intranasal norovirus vaccine given 21 days apart in 90-115 healthy adult volunteers. The v...